Nuwellis Inc (NASDAQ:NUWE) shares are surging Thursday afternoon as traders react to new pediatric data tied to the company’s Aquadex ultrafiltration therapy.

• Nuwellis stock is showing exceptional strength. What’s fueling NUWE momentum?

What Is Driving Nuwellis’ Stock Surge?

Nuwellis said a new single-center retrospective study supporting an alternative anticoagulation strategy for Aquadex ultrafiltration therapy was accepted by Frontiers in Pediatrics, highlighting epoprostenol as a potential option for keeping circuits open without adding bleeding risk or requiring intensive metabolic monitoring.

The company also noted it provided modest financial support to underwrite open-access publication costs, but did not fund the conduct of the research.

Nuwellis’ rally is also being framed by traders as a continuation of its pediatric push after it installed its first Aquadex SmartFlow systems at a leading pediatric hospital in Wisconsin.

That installation followed preliminary second-quarter revenue growth of 14% year over year (and 20% growth for the six-month period ended June 30), keeping attention on the Aug. 13 results date.

Nuwellis Stock Price Activity Update

NUWE Stock Price Activity: Nuwellis shares were up 136.77% at $4.48 at the time of publication on Thursday, according to Benzinga Pro data.

Image: Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.